Tumor Necrosis Factor Inhibitors Archives

Observational studies of patients with RA have shown that change in PROs like patient global disease assessment, pain, function, and fatigue correspond with objective measures of disease activity. In an observational trial of patients with RA treated with adalimumab, 68% of patients with objective improvement in disease activity after 1 year of treatment had significant improvement in pain, 39% had significant improvement in fatigue, and 42% had significant improvement in function. Only 23% of patients with an objective therapeutic response had no significant change in any PRO assessed. Conversely, in the cohort of patients who did not have objective improvement, rates of significant improvement for pain, fatigue, and function were 29%, 15%, and 17%, respectively.4 Other studies have found that in addition to providing an accurate measure of treatment response, PROs are good predictors of long-term outcomes.4

TNF and Non-TNF Inhibitors Display Comparable Effectiveness for Rheumatoid Arthritis Treatment

By

Emily Pond

August 14, 2020

Researchers evaluated the effectiveness of tumor necrosis factor (TNF) vs non-TNF inhibitors in the treatment of rheumatoid arthritis.

Rheumatoid Arthritis

Clinically Validated Blood-Based Test Predicts Response to Anti-TNF Therapies in RA

By

Morgan E. Meissner

August 11, 2020

Researchers developed a molecular test that predicts inadequate response to anti-TNF therapies in biologic-naive patients with rheumatoid arthritis.

Spondyloarthritis

Treatment With TNF Inhibitors Slows Radiographic Progression in Ankylosing Spondylitis

By

Amit Akirov, MD

August 4, 2020

Researchers evaluated the long-term treatment with tumor necrosis factor inhibitors on radiographic progression in patients with ankylosing spondylitis.

Senior woman with joint pain in her hand

Spondyloarthritis

Pain and Fatigue in PsA Linked to Reduced Quality of Life, Physical Function, and Work Productivity

By

Alyssa Capel

July 10, 2020

Researchers evaluated the frequency and severity of pain and fatigue in patients with psoriatic arthritis receiving tumor necrosis factor inhibitors.

Spondyloarthritis

Fewer Patients in the Real-World vs Clinical Trials May Achieve Satisfactory Response to TNFis in axSpA

By

Alyssa Capel

May 18, 2020

Researchers investigated the treatment response of patients receiving tumor necrosis factor inhibitors in the real-world vs clinical trials.

Rheumatoid Arthritis

Anti-TNF Agents May Lower Alzheimer Disease Risk for Psoriasis, Rheumatoid Arthritis

By

Emily Pond

May 13, 2020

A subset of patients at risk for Alzheimer disease because of systemic inflammation may benefit from receiving a tumor necrosis factor (TNF) blocking agent.

Spondyloarthritis

TNFi Combination Therapy vs Monotherapy Improves Drug Survival in Psoriatic Arthritis

By

Yellowlees Douglas, PhD

May 11, 2020

Researchers compared the effectiveness of tumor necrosis factor inhibitor combination therapy vs monotherapy in psoriatic arthritis.

Rheumatoid Arthritis

Demographic Characteristics and Clinical Factors Affect Anti-TNF Treatment Adherence in Rheumatoid Arthritis

By

Rheumatology Advisor Contributing Writer

March 20, 2020

Researchers determined the adherence to subcutaneous antitumor necrosis factor agents in rheumatoid arthritis, and evaluated the influence of injection site pain and skin perceptions on treatment adherence.